Botanical Extract Modulation of Glucose Homeostasis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapeutic strategies targeting skeletal muscle to improve insulin sensitivity in type 2 diabetes have had limited success due to concerns about selectivity and the risk of hypoglycemia, and existing methods fail to capture the therapeutic potential of compound interactions in complex mixtures like PMI-5011.

Innovation Solution

The use of a botanical extract PMI-5011, comprising components such as methyldavidigenin, DMC-2, and other naturally derived or synthetically produced compounds, which are administered to enhance insulin signaling and glucose homeostasis by synergistically reducing blood glucose levels and modulating insulin sensitivity in skeletal muscle.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If small organic molecules are used as insulin receptor potentiators or PTP1B inhibitors to increase insulin sensitivity in skeletal muscle, then insulin sensitivity is improved, but selectivity and risk of hypoglycemia worsen

Engineering Contradiction:

Improveinsulin sensitivityVSAvoidhypoglycemia risk

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and isolates specific bioactive compounds (PTP1B inhibitors and insulin receptor potentiators) from complex natural product mixtures. By identifying and separating the active components responsible for insulin sensitivity enhancement, the invention enables targeted delivery of therapeutic effects while minimizing unwanted side effects associated with crude extracts.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The invention optimizes the chemical structure and pharmacological parameters of isolated compounds to improve their selectivity profile. By modifying molecular parameters such as binding affinity, specificity constants, and metabolic stability, the patent develops compounds that selectively enhance insulin signaling in muscle tissue without causing systemic hypoglycemia.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If complex botanical extracts like PMI-5011 are used to treat diabetes, then therapeutic potential is enhanced, but difficulty in detecting and measuring compound interactions worsens

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidcompound interaction analysis

Core Design Contradiction:

ReliabilityVSDifficulty of detecting and measuring

Solution Approach 1:

The patent segments complex botanical extracts into individual bioactive compounds or small groups of synergistic compounds. By fractionating the crude extract and isolating specific constituents, the invention makes it possible to study each compound's mechanism of action and their interactions separately, while still preserving the therapeutic benefits of combination therapy.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent uses cell-free biochemical assays and purified protein systems as intermediaries to study compound interactions. By measuring effects on isolated enzymes (such as PTP1B activity assays) or signaling pathways in controlled in vitro systems, the invention enables precise quantification of compound interactions without the complexity of whole-cell or whole-organism systems.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20230045522A1Compositions and methods to modulate glucose homeostasis

Publication Date: 2023.02.09 BOARD OF SUPERVISORS OF LOUISIANA STATE UNIV & AGRI & MECHANICAL COLLEGE

AI summary

This invention is directed to compositions and methods for modulating glucose homeostasis.